CSUR—the Research Institute Supporting Juul and NJOY’s successful PMTAs—assessed FDA’s pilot for nicotine pouches. The program expedites premarket review by deferring behavioral data to post-market reporting. CSUR says this could speed authorizations, but manufacturers must still produce behavioral and real-world evidence after a Marketing Granted Order to maintain compliance with public-health standards.

As global delegates prepare for COP11, a leaked EU position paper has sparked fresh debate over the future of nicotine pouch regulation. In an exclusive op-ed submitted to 2Firsts, Dr. Nveed Chaudhary, Chair of GINN’s Scientific Committee, argues that banning nicotine pouches would be a profound public health mistake—one that ignores harm reduction science and risks reversing global progress in smoking cessation.

As Russia’s federal vape policy stalls, regional governors are racing to implement local bans—now with the backing of President Vladimir Putin. The divide between swift local action and delayed national legislation is fueling debate over health, regulation, and the country’s broader approach to nicotine control.

This opinion piece, submitted by Samrat Chowdhery to 2Firsts, challenges the logic of tobacco price elasticity. It argues that high taxes often harm vulnerable populations and fuel illicit markets rather than reducing smoking.

Amid intensified regulation and sweeping market shifts, the U.S. vaping industry is undergoing a profound transformation. In an exclusive interview with 2Firsts, AVM President Allison Boughner discusses how enforcement is reshaping brands, distribution, products, compliance, and U.S.-based manufacturing.